EBNA1 inhibitors and their method of use

A method of treating or ameliorating a disease caused by EBNA1 activity in a subject, wherein the disease caused by EBNA1 activity is at least one selected from the group consisting of infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis,

• the method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:
• 2-(1-methyl-1H-indol-5-yl)-3-[2-(1,3-thiazol-4-yl) ethynyl] benzoic acid;
• 2-(3-(Methoxycarbonyl)-1H-indol-6-yl)-3-(thiazol-4-ylethynyl) benzoic acid;
• 2-(1H-indol-6-yl)-3-(thiazol-4-ylethynyl) benzoic acid;
• 3-((6-aminopyridin-2-yl) ethynyl)-2-(1H-indol-6-yl) benzoic acid;
• 3-((2-aminopyridin-4-yl) ethynyl)-2-(1H-indol-6-yl) benzoic acid;
• 2-(1H-indol-6-yl)-3-[2-(pyridin-4-yl) ethynyl] benzoic acid;
• and
• or a salt or solvate thereof.

A method of treating or ameliorating Epstein-Barr Virus infection in a subject, the method comprising administering to the subject an effective amount of a compound of Formula (IX):

• or a solvate or salt thereof, wherein:
• R1 is selected from the group consisting of optionally substituted thiazolyl, optionally substituted pyridyl, optionally substituted benzyl,
• R2 is
• R3 is CO2R4d;
• R4d is selected from the group consisting of hydrogen, optionally substituted C1-6 linear alkyl, and optionally substituted C3-6 branched alkyl;
• R8a, R8b, R8c, R8d, and R8e are each independently selected from the group consisting of hydrogen, optionally substituted C1-6 linear alkyl, and optionally substituted C3-6 branched alkyl;
• R9a, R9b, R9c, R9d, and R9e are each independently selected from the group consisting of hydrogen, optionally substituted C1-6 linear alkyl, and optionally substituted C3-6 branched alkyl;
• L2 is (CH2)m;
• and
• m is 0, 1, 2, or 3;
• optionally wherein the compound is administered as part of a composition further comprising at least one excipient.

A method of treating or ameliorating Epstein-Barr Virus (EBV) infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:

• 2-(1-methyl-1H-indol-5-yl)-3-[2-(1,3-thiazol-4-yl) ethynyl] benzoic acid;
• 2-(3-(Methoxycarbonyl)-1H-indol-6-yl)-3-(thiazol-4-ylethynyl) benzoic acid;
• 2-(1H-indol-6-yl)-3-(thiazol-4-ylethynyl) benzoic acid;
• 3-((6-aminopyridin-2-yl) ethynyl)-2-(1H-indol-6-yl) benzoic acid;
• 3-((2-aminopyridin-4-yl) ethynyl)-2-(1H-indol-6-yl) benzoic acid;
• 2-(1H-indol-6-yl)-3-[2-(pyridin-4-yl) ethynyl] benzoic acid;
• and
• or a salt or solvate thereof.